|
Real-time Estimate
Cboe BZX
11:48:31 2026-09-18 EDT
|
5-day change | 1st Jan Change | ||
| 26.63 USD | -0.71% |
|
+26.46% | - |
| 07:43am | BlossomHill Therapeutics Q2 Loss Widens | MT |
| 07:14am | Earnings Flash (BLSM) BlossomHill Therapeutics Posts Q2 Loss $8.75 a Share | MT |
Projected Income Statement: BlossomHill Therapeutics, Inc.
| Fiscal Period: December | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| Net sales 1 | - | - | - | - |
| Change | - | - | - | - |
| EBITDA 1 | - | -112 | -136 | -159 |
| Change | - | - | -21.43% | -16.91% |
| EBIT 1 | - | -106 | -130.1 | -161.5 |
| Change | - | - | -22.76% | -24.15% |
| Interest Paid | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -100 | -122.1 | -157.6 |
| Change | - | - | -22.07% | -29.05% |
| Net income 1 | -60.56 | -101.2 | -121.4 | -153.4 |
| Change | - | -67.08% | -19.98% | -26.33% |
| Announcement Date | 4/24/26 | - | - | - |
1USD in Million
Estimates
Forecast Balance Sheet: BlossomHill Therapeutics, Inc.
| Fiscal Period: December | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| Net Debt | - | - | - | - |
| Change | - | - | - | - |
| Announcement Date | 4/24/26 | - | - | - |
Estimates
Cash Flow Forecast: BlossomHill Therapeutics, Inc.
| Fiscal Period: December | 2026 | 2027 | 2028 |
|---|---|---|---|
| CAPEX 1 | 0.425 | 0.525 | 1 |
| Change | - | 23.53% | 90.48% |
| Free Cash Flow (FCF) 1 | -93.55 | -113 | -95.45 |
| Change | - | -20.79% | 15.53% |
| Announcement Date | - | - | - |
1USD in Million
Estimates
Forecast Financial Ratios: BlossomHill Therapeutics, Inc.
| Fiscal Period: December | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
Profitability | ||||
| EBITDA Margin (%) | - | - | - | - |
| EBIT Margin (%) | - | - | - | - |
| EBT Margin (%) | - | - | - | - |
| Net margin (%) | - | - | - | - |
| FCF margin (%) | - | - | - | - |
| FCF / Net Income (%) | - | 92.46% | 93.08% | 62.24% |
Profitability | ||||
| ROA | - | -56.86% | -79.62% | -150.01% |
| ROE | - | -74.36% | -118% | -351.04% |
Financial Health | ||||
| Leverage (Debt/EBITDA) | - | - | - | - |
| Debt / Free cash flow | - | - | - | - |
Capital Intensity | ||||
| CAPEX / Current Assets (%) | - | - | - | - |
| CAPEX / EBITDA (%) | - | -0.38% | -0.39% | -0.63% |
| CAPEX / FCF (%) | - | -0.45% | -0.46% | -1.05% |
Items per share | ||||
| Cash flow per share 1 | - | - | - | - |
| Change | - | - | - | - |
| Dividend per Share 1 | - | - | - | - |
| Change | - | - | - | - |
| Book Value Per Share 1 | - | - | - | - |
| Change | - | - | - | - |
| EPS 1 | -5.3 | -3.824 | -3.289 | -3.474 |
| Change | - | 27.85% | 14% | -5.62% |
| Nbr of stocks (in thousands) | - | 30,644 | 30,644 | 30,644 |
| Announcement Date | 4/24/26 | - | - | - |
1USD
Estimates
| 2026 * | 2027 * | |
|---|---|---|
| P/E | -7.01x | -8.15x |
| PBR | - | - |
| EV / Sales | - | - |
| Yield | - | - |
EPS & Dividend
Y-o-Y evolution of P/E
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
26.82USD
Average target price
32.20USD
Spread / Average Target
+20.06%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BLSM Stock
- Financials BlossomHill Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
